drug discovery
insitro unveiled a $143 million Series B round on the same day that fellow machine learning company Exscientia highlighted its own $60 million Series C raise.
Bayer and Exscientia will initially work on three early-stage projects using AI to speed up drug discovery.
In a recent medium.
BenevolentAI, a UK company using artificial intelligence for drug development, has raised $115 million in new funding, mostly from undisclosed investors in the United States.